Skip to main content
NCBI home page
Cellular & Molecular Biology Letters logoLink to Cellular & Molecular Biology Letters
. 2008 May 6;13(3):465. doi: 10.2478/s11658-008-0014-9

Lipid changes occuring in the course of hematological cancers

Małgorzata Kuliszkiewicz-Janus 1,2,✉, Rafał Małecki 3, Abdulrahman Saeed Mohamed 1
PMCID: PMC6275614  PMID: 18463797

Abstract

The relationship between plasma lipid levels and mortality from cardiovascular diseases has been shown in many studies, but there has been far less investigation into their relationship to non-cardiovascular diseases. The aim of this study was to investigate the lipid profile of individuals with hematological malignancies and its relationship to disease activity. 238 patients were included in the study: 84 with acute leukemia, 62 with non-Hodgkin lymphoma, 35 with Hodgkin’s lymphoma, 32 with multiple myeloma, and 25 with myeloproliferative syndrome. The HDL cholesterol level of the patients differed to that of the individuals in the control group in the active disease period for all the analyzed disorders, but only remained statistically significant in the acute leukemia and non-Hodgkin lymphoma groups during the remission period. Smaller differences were observed for the remaining lipid fractions, except for the triglyceride level, which increased in the active disease period in all the analyzed disorders except non-Hodgkin lymphoma. The most pronounced changes in the lipid fractions occurred in the HDL cholesterol level, and were the most remarkable for acute leukemia.

Key words: Lipid profile, HDL-C, Hematological cancers

Full Text

The Full Text of this article is available as a PDF (382.6 KB).

Abbreviations used

HDL-C

high-density lipoprotein cholesterol

LDL-C

low-density lipoprotein cholesterol

TC

total cholesterol

References

  • 1.Castelli W.P., Garrison R.J., Wilson P.W., Abbott R.D., Kalousdian S., Kannel W.B. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA. 1986;256:2835–2738. doi: 10.1001/jama.256.20.2835. [DOI] [PubMed] [Google Scholar]
  • 2.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet344 (1994) 1383–1389. [PubMed]
  • 3.Kreger B.E., Anderson K.M., Schatzkin A., Splansky G.L. Serum cholesterol level, body mass index, and the risk of colon cancer. The Framingham Study. Cancer. 1992;70:1038–1043. doi: 10.1002/1097-0142(19920901)70:5<1038::AID-CNCR2820700505>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  • 4.Sherwin R.W., Wentworth D.N., Cutler J.A., Hulley S.B., Kuller L.H., Stamler J. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA. 1987;257:943–948. doi: 10.1001/jama.257.7.943. [DOI] [PubMed] [Google Scholar]
  • 5.Fiorenza A.M., Branchi A., Sommariva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int. J. Clin. Lab. Res. 2000;30:141–145. doi: 10.1007/s005990070013. [DOI] [PubMed] [Google Scholar]
  • 6.Musolino C., Calabro L., Bellomo G., Cincotta M., Di Giacomo V., Pezzano C., Loteta B., Rizzo V., Guglielmo S., Alonci A. Lipid profile in hematologic neoplasms. Recenti Prog. Med. 2002;93:298–301. [PubMed] [Google Scholar]
  • 7.Dessi S., Batetta B., Pulisci D., Accogli P., Pani P., Broccia G. Total and HDL cholesterol in human hematologic neoplasms. Int. J. Hematol. 1991;54:483–486. [PubMed] [Google Scholar]
  • 8.Scribano D., Baroni S., Pagano L., Zuppi C., Leone G., Giardina B. Return to normal values of lipid pattern after effective chemotherapy in acute lymphoblastic leukemia. Haematologica. 1996;81:343–345. [PubMed] [Google Scholar]
  • 9.Moschovi M., Trimis G., Apostolakou F., Papassotiriou I., Tzortzatou-Stathopoulou F. Serum lipid alterations in acute lymphoblastic leukemia of childhood. J. Pediatr. Hematol. Oncol. 2004;26:289–293. doi: 10.1097/00043426-200405000-00006. [DOI] [PubMed] [Google Scholar]
  • 10.Kuliszkiewicz-Janus M., Tuz M.A., Baczyński S. Application of 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. Biochim. Biophys. Acta. 2005;1737:11–15. doi: 10.1016/j.bbalip.2005.08.019. [DOI] [PubMed] [Google Scholar]
  • 11.Lorenc J., Kozak-Michałowska I., Polkowska-Kulesza E. Disorders of lipid and lipoprotein metabolism in patients with chronic lymphocytic leukemia. I. Preliminary evaluation of lipemia and HDL fractions in various stages of the disease. Przegl. Lek. 1989;46:713–718. [PubMed] [Google Scholar]
  • 12.Ginsberg H.N., Le N.A., Gilbert H.S. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35:878–882. doi: 10.1016/0026-0495(86)90232-5. [DOI] [PubMed] [Google Scholar]
  • 13.Gilbert H.S., Ginsberg H. Hypocholesterolemia as a manifestation of disease activity in chronic myelocytic leukemia. Cancer. 1983;51:1428–1433. doi: 10.1002/1097-0142(19830415)51:8<1428::AID-CNCR2820510817>3.0.CO;2-X. [DOI] [PubMed] [Google Scholar]
  • 14.Ghalaut V.S., Pahwa M.B., Sunita, Ghalaut P.S. Alteration in lipid profile in patients of chronic myeloid leukemia before and after chemotherapy. Clin. Chim. Acta. 2006;366:239–428. doi: 10.1016/j.cca.2005.10.022. [DOI] [PubMed] [Google Scholar]
  • 15.Hachem H., Favre G., Ghalim N., Puchois P., Fruchart J.C., Soula G. Quantitative abnormalities of lipoprotein particles in multiple myeloma. J. Clin. Chem. Clin. Biochem. 1987;25:675–679. doi: 10.1515/cclm.1987.25.10.675. [DOI] [PubMed] [Google Scholar]
  • 16.Kuliszkiewicz-Janus M., Baczyński S. Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma. NMR Biomed. 1995;8:127–132. doi: 10.1002/nbm.1940080308. [DOI] [PubMed] [Google Scholar]
  • 17.Kuliszkiewicz-Janus M., Baczyński S. Application of 31P NMR spectroscopy to monitor chemotherapy-associated changes of serum phospholipids in patients with malignant lymphomas. Magn. Reson. Med. 1996;35:449–456. doi: 10.1002/mrm.1910350402. [DOI] [PubMed] [Google Scholar]
  • 18.van Leeuwen H.J., Heezius E.C., Dallinga G.M., van Strijp J.A., Verhoef J., van Kessel K.P. Lipoprotein metabolism in patients with severe sepsis. Crit. Care Med. 2003;31:1359–1366. doi: 10.1097/01.CCM.0000059724.08290.51. [DOI] [PubMed] [Google Scholar]
  • 19.Sakashita A.M., Bydlowski S.P., Chamone D.A., Maranhao R.C. Plasma kinetics of an artificial emulsion resembling chylomicrons in patients with chronic lymphocytic leukemia. Ann. Hematol. 2000;79:687–690. doi: 10.1007/s002770000205. [DOI] [PubMed] [Google Scholar]
  • 20.Baroni S., Scribano D., Zuppi C., Pagano L., Leone G., Giardina B. Prognostic relevance of lipoprotein cholesterol levels in acute lymphocytic and nonlymphocytic leukemia. Acta Haematol. 1996;96:24–28. doi: 10.1159/000203710. [DOI] [PubMed] [Google Scholar]
  • 21.Moran C.S., Campbell J.H., Campbell G.R. Human leukemia inhibitory factor upregulates LDL-C receptors on liver cells and decreases serum cholesterol in the cholesterol-fed rabbit. Arterioscler. Thromb. Vasc. Biol. 1997;17:1267–1273. doi: 10.1161/01.atv.17.7.1267. [DOI] [PubMed] [Google Scholar]
  • 22.Goncalves R.P., Rodrigues D.G., Maranhao R.C. Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells. Leuk. Res. 2005;29:955–959. doi: 10.1016/j.leukres.2005.01.013. [DOI] [PubMed] [Google Scholar]

Articles from Cellular & Molecular Biology Letters are provided here courtesy of BMC

RESOURCES